drugset / Trial / NCT03815084
A Study of PD1 Combined With DC-NK Cell in the Treatment of Solid Tumors
Phase 0
Unknown
100 enrolled
Allife Medical Science and Technology Co., Ltd.
Beijing Hospital · collabHenan Provincial People's Hospital · collabThe First People's Hospital of Yunnan · collab
NaSingle-groupOpen-labelHealth-services research
Summary
clinical study on the safety and efficacy of PD1 combined with dc-Nk in the treatment of solid tumors
Timeline
- Start
- 2019-02-01
- Primary completion
- 2020-02-01
- Completion
- 2021-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DC cells | Cell therapy | 6e+07 cells | — |
| Subject | NK cells | Cell therapy | 3e+09 cells | — |
| Subject | Pembrolizumab | Monoclonal antibody | 10 ml | — |